These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22030027)

  • 21. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
    Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
    J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluorescent phosphoinositide 3-kinase inhibitors suitable for monitoring of intracellular distribution.
    Kim D; Lee H; Jun H; Hong SS; Hong S
    Bioorg Med Chem; 2011 Apr; 19(8):2508-16. PubMed ID: 21459582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Think twice: understanding the high potency of bis(phenyl)methane inhibitors of thrombin.
    Baum B; Muley L; Heine A; Smolinski M; Hangauer D; Klebe G
    J Mol Biol; 2009 Aug; 391(3):552-64. PubMed ID: 19520086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
    Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
    J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Insights into PI3K Inhibitor Design using X-ray Structures of PI3Kα Complexed with a Potent Lead Compound.
    Yang X; Zhang X; Huang M; Song K; Li X; Huang M; Meng L; Zhang J
    Sci Rep; 2017 Nov; 7(1):14572. PubMed ID: 29109464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.
    Gonzalez-Lopez de Turiso F; Shin Y; Brown M; Cardozo M; Chen Y; Fong D; Hao X; He X; Henne K; Hu YL; Johnson MG; Kohn T; Lohman J; McBride HJ; McGee LR; Medina JC; Metz D; Miner K; Mohn D; Pattaropong V; Seganish J; Simard JL; Wannberg S; Whittington DA; Yu G; Cushing TD
    J Med Chem; 2012 Sep; 55(17):7667-85. PubMed ID: 22876881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 9-(1-phenoxyethyl)-2-morpholino-4-oxo-pyrido[1,2-a]pyrimidine-7-carboxamides as oral PI3Kβ inhibitors, useful as antiplatelet agents.
    Giordanetto F; Barlaam B; Berglund S; Edman K; Karlsson O; Lindberg J; Nylander S; Inghardt T
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3936-43. PubMed ID: 25042253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of a novel aminopyrazine series as selective PI3Kα inhibitors.
    Barlaam B; Cosulich S; Fitzek M; Germain H; Green S; Hanson LL; Harris CS; Hancox U; Hudson K; Lambert-van der Brempt C; Lamorlette M; Magnien F; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
    Bioorg Med Chem Lett; 2017 Jul; 27(13):3030-3035. PubMed ID: 28526367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold.
    Barlaam B; Cosulich S; Fitzek M; Green S; Harris CS; Hudson K; Lambert-van der Brempt C; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2679-85. PubMed ID: 25980912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3Kβ inhibitors.
    Certal V; Halley F; Virone-Oddos A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Delorme C; Karlsson A; Abecassis PY; Vincent L; Bonnevaux H; Nicolas JP; Morales R; Michot N; Vade I; Louboutin A; Perron S; Doerflinger G; Tric B; Monget S; Lengauer C; Schio L
    Bioorg Med Chem Lett; 2012 Oct; 22(20):6381-4. PubMed ID: 22981333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
    Talele TT; McLaughlin ML
    J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel type II c-Met inhibitors based on BMS-777607.
    Zhang W; Ai J; Shi D; Peng X; Ji Y; Liu J; Geng M; Li Y
    Eur J Med Chem; 2014 Jun; 80():254-66. PubMed ID: 24792774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
    Kim O; Jeong Y; Lee H; Hong SS; Hong S
    J Med Chem; 2011 Apr; 54(7):2455-66. PubMed ID: 21388141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
    Sturgeon SA; Jones C; Angus JA; Wright CE
    Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and antiplatelet activity of a selective PI3Kβ inhibitor (MIPS-9922).
    Zheng Z; Pinson JA; Mountford SJ; Orive S; Schoenwaelder SM; Shackleford D; Powell A; Nelson EM; Hamilton JR; Jackson SP; Jennings IG; Thompson PE
    Eur J Med Chem; 2016 Oct; 122():339-351. PubMed ID: 27387421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of novel xanthone derivatives as xanthine oxidase inhibitors.
    Hu L; Hu H; Wu W; Chai X; Luo J; Wu Q
    Bioorg Med Chem Lett; 2011 Jul; 21(13):4013-5. PubMed ID: 21620698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells.
    Bénistant C; Chapuis H; Roche S
    Oncogene; 2000 Oct; 19(44):5083-90. PubMed ID: 11042696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SAR studies around a series of triazolopyridines as potent and selective PI3Kγ inhibitors.
    Bell K; Sunose M; Ellard K; Cansfield A; Taylor J; Miller W; Ramsden N; Bergamini G; Neubauer G
    Bioorg Med Chem Lett; 2012 Aug; 22(16):5257-63. PubMed ID: 22819766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.